September 4, 2019 Clinical Research/Diagn. Mass Spectrometry Product Launch

Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)

Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today announced the launch of three new Imaging Mass Cytometry™ Maxpar® Human Immuno-Oncology Panel Kits and an advanced CyTOF® Software solution at the World... Read more

September 3, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Announces Collaboration to Develop Advanced Analytical Workflows for Clinical Laboratories

Thermo Fisher Scientific Announces Collaboration to Develop Advanced Analytical Workflows for Clinical Laboratories SAN JOSE, Calif., Sept. 3, 2019 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Cedars-Sinai, a leading nonprofit academic healthcare organization, have entered into a collaboration to develop a pathway to precision medicine through the development of robust,... Read more

September 3, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 03 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more

August 29, 2019 Clinical Research/Diagn. Licensing, IP, and Legal Product Launch

Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

Basel, 29 August 2019 Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq This launch represents an important step in Roche’s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine Each year 300,000... Read more

August 21, 2019 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal

Clinical Study Published in Prenatal Diagnosis Further Validates PerkinElmer’s Vanadis Fully Automated NIPT Platform

CE-Marked Solution Gives Pregnant Women Widespread Access to Non-Invasive Prenatal Testing WALTHAM, Mass. – August 21, 2019 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its Vanadis® fully automated non-invasive prenatal testing (NIPT) system has been validated in an external clinical study, titled “Clinical Validation of a... Read more

August 19, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

NUS, Agilent, and NUH launch new translational R&D hub to boost clinical diagnostics

NUS, Agilent, and NUH launch new translational R&D hub to boost clinical diagnostics S$38 million research facility aims to be a premier, global, one-stop hub for research and translation to clinical testing through biochemical innovation and techniques Singapore, 19 August 2019 The National University of Singapore (NUS), Agilent Technologies, a global leader in life sciences,... Read more

August 14, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Liq. Handling & Robotics Product Launch

QIAGEN’s new QIAstat-Dx Gastrointestinal Panel demonstrates excellent performance in multicenter clinical study in Europe

Hilden, Germany, and Germantown, Maryland, August 14, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis. The QIAstat-Dx Gastrointestinal Panel delivered high performance compared to other, existing multiplex tests in this... Read more

August 9, 2019 Clinical Research/Diagn. PR/Corporate

Quanterix Prices Public Offering of Common Stock

AUGUST 09, 2019 BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share. All of the shares... Read more

August 7, 2019 Clinical Research/Diagn. PR/Corporate

Quanterix Announces Proposed Public Offering of Common Stock

AUGUST 08, 2019 August 07, 2019 04:23 PM Eastern Daylight Time BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In connection with the... Read more

August 7, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships Mass Spectrometry

Development of multiplexed quantitation assay in circulation for therapeutic antibody monitoring of inflammatory immune diseases using nSMOL Antibody BA Kit

nSMOL™ Antibody BA Pretreatment Kit Shimadzu Corporation and Kyoto University developed the novel assay method of multiplexed analysis of therapeutic antibodies for the treatment of inflammatory immune diseases.1) The antibodies were measured using an LCMS-8050/8060 high-performance liquid chromatograph triple quadrupole mass spectrometer and nSMOLTM Antibody BA Kit2). The results of the joint research were published on... Read more